Treatment for Critically Ill COVID Patients Begins 1st Randomized Clinical Trial. Study to Investigate ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter’s. Ability to Reduce ICU Length of Stay and Mortality Rate

MARTINEZ, Calif. – Physicians across the country are using ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) under emergency use authorization from the U.S. Food and Drug Administration to treat critically ill COVID patients resulting in statistically significant improvements in 63% survival rate among patients whose blood was filtered with the Seraph 100.